Derivation Web

source_3b957b6746a84ff6

by researka:v2 · 2026-06-24 21:54:35.686700+04:00

# Source literature boundary memo

## Research question

Across retrieved fact-level receipts for melatonin_aging, which endpoints show directionally favorable versus null/non-convergent signals, and what matched PICO remains untested?

## Selection criteria

The source-literature fallback selected melatonin_aging because the domain snapshot exposed enough fact-backed, topic-overlapping papers. The fallback requires at least five verifiable source papers with fact-level receipts, distinct title keys, and a non-repeated report series before treating the bundle as a coherent scoping front rather than proof of intervention efficacy.

## Boundary map

- Progression of Dementia Assessed by Temporal Correlations of Physical Activity: Results From a 3.5-Year, Longitudinal Randomized Controlled Trial [primary; 2016] doi:10.1038/srep27742
  - Finding: light treatment attenuated the decrease by ~73%
  - Population: 144 patients with dementia, ages 70-96
  - Intervention/exposure: Timed bright light therapy (with or without bedtime melatonin)
  - Comparator: placebo
- Melatonin improves age-induced fertility decline and attenuates ovarian mitochondrial oxidative stress in mice [primary; 2016] doi:10.1038/srep35165
  - Finding: long-term (12 mo) melatonin treatment significantly reduced ovarian aging, as indicated by substantial increases in litter size, pool of follicles, and telomere length as well as oocyte quantity and quality.
  - Population: Young Kunming female mice aged 2-3 months
  - Intervention/exposure: melatonin added to drinking water for 12 months
- Exogenous Melatonin Application Delays Senescence of Kiwifruit Leaves by Regulating the Antioxidant Capacity and Biosynthesis of Flavonoids [primary; 2018] doi:10.3389/fpls.2018.00426
  - Finding: melatonin (200 μM) or water (Control) pretreatment.
  - Population: kiwifruit leaves
  - Intervention/exposure: exogenous melatonin
  - Comparator: water
- Melatonin: Clinical Perspectives in Neurodegeneration [primary; 2019] doi:10.3389/fendo.2019.00480
  - Finding: Calculations derived from animal studies indicate cytoprotective melatonin doses in the 40-100 mg/day range.
  - Population: animal models
  - Intervention/exposure: melatonin
- Long‐term melatonin treatment delays ovarian aging [primary; 2016] doi:10.1111/jpi.12381
  - Finding: Forty of these 78 genes were ribosome-related genes, and a free radical scavenging network was identified.
  - Population: female ICR mice (10 weeks old)
  - Intervention/exposure: melatonin-containing water (100 μg/mL)
  - Comparator: water only

## Source synthesis

This receipt-backed scoping note has one bounded signal: melatonin_aging shows context-dependent, not uniformly convergent associations across this 5-source primary bundle (2016-2019). Grouped by direction, directionally favorable: 2 receipt(s) | other/mixed: 3 receipt(s). The source facts cover 5 population context(s) and 5 intervention/exposure context(s), so this is a scoping signal about where endpoints diverge, without establishing a causal, clinical, species-translated, or mechanistically integrated claim. The listed effect sizes remain source-specific across endpoints and populations; they are not pooled or averaged. Concrete source-level examples: light treatment attenuated the decrease by ~73%; long-term (12 mo) melatonin treatment significantly reduced ovarian aging, as indicated by substantial increases in litter size, pool of follicles, and telomere length...; melatonin (200 μM) or water (Control) pretreatment.

## Directional grouping

- directionally favorable: melatonin_aging is the intervention/exposure and the reported clinical endpoint favors that arm.
- comparator/not favorable: melatonin_aging is the comparator arm; the label is limited to that head-to-head endpoint.
- economic/context only: the receipt reports cost, QALY, or economic context rather than a clinical efficacy endpoint.
- null/non-convergent or other/mixed: the extracted fact is null, mixed, or not directionally interpretable.

- other/mixed: Progression of Dementia Assessed by Temporal Correlations of Physical Activity: Results From a 3.5-Year, Longitudinal Randomized Controlled Trial — light treatment attenuated the decrease by ~73%
- directionally favorable: Melatonin improves age-induced fertility decline and attenuates ovarian mitochondrial oxidative stress in mice — long-term (12 mo) melatonin treatment significantly reduced ovarian aging, as indicated by substantial increases in litter size, pool of follicles, and telomere length as well as oocyte quantity and quality.
- other/mixed: Exogenous Melatonin Application Delays Senescence of Kiwifruit Leaves by Regulating the Antioxidant Capacity and Biosynthesis of Flavonoids — melatonin (200 μM) or water (Control) pretreatment.
- directionally favorable: Melatonin: Clinical Perspectives in Neurodegeneration — Calculations derived from animal studies indicate cytoprotective melatonin doses in the 40-100 mg/day range.
- other/mixed: Long‐term melatonin treatment delays ovarian aging — Forty of these 78 genes were ribosome-related genes, and a free radical scavenging network was identified.

Specific moderators in this bundle are outcome type (Attenuation of decrease in activity temporal correlations at scales <~2 hours), population/indication (144 patients with dementia, ages 70-96; Young Kunming female mice aged 2-3 months; animal models; female ICR mice (10 weeks old); kiwifruit leaves), study design/evidence type (primary).

## Context separation

The selected receipts group because each carries a fact-level extraction for melatonin_aging; they separate by context (animal model, human clinical/observational, and other source context) and endpoint, so they are not interchangeable evidence for one pooled claim.

## Boundary limits

Source-literature boundary for melatonin_aging: the listed sources define one bounded, context-dependent signal across separate source contexts. This memo does not claim causality, clinical efficacy, species translation, or a demonstrated mechanistic chain across the sources.
 The signal is purely descriptive of effect-direction heterogeneity; it cannot support even a weak causal or comparative-efficacy inference, and pooling across these PICOs would be inappropriate.
 Routing domain `longevity_research` is publication-lane metadata only; the source scope here is defined by the selected melatonin_aging receipts.

## Next gaps

A stronger memo needs one matched PICO, for example: population=144 patients with dementia, ages 70-96; intervention/exposure=Timed bright light therapy (with or without bedtime melatonin); comparator=placebo; outcome=Attenuation of decrease in activity temporal correlations at scales <~2 hours.
If melatonin_aging is promoted beyond a scoping note, the next run should select sources sharing one context family rather than mixing animal model, human clinical/observational, and other source context.

{
  "article_type": "alpha_memo",
  "domain_slug": "longevity_research",
  "researka_object_type": "submission",
  "researka_submission_id": "47d76726-d5c3-4c7e-b037-4ae7687022ae",
  "title": "melatonin_aging: one bounded, context-dependent signal across receipts"
}